Oscar Health (OSCR) is drawing fresh attention after launching its Lucie Health Marketplace, an all-in-one storefront for individual and employer health benefits, as investors also look ahead to the company’s upcoming earnings report.

At a share price of $18.49, Oscar Health has seen strong recent momentum, with a 30 day share price return of 55.12% and a 1 year total shareholder return of 40.08%. This builds on a very large 3 year total shareholder return, as attention clusters around Lucie and upcoming earnings alongside recent board changes.

If Lucie’s launch has you rethinking where technology meets healthcare, it could be a good moment to scan for other opportunities in AI driven health using the Simply Wall St screener for 33 healthcare AI stocks

With the share price running well ahead of recent analyst targets and excitement building around Lucie and earnings, the key question now is whether Oscar Health is trading below its underlying value or if the market is already pricing in the growth story.

Most Popular Narrative: 20.1% Overvalued

Oscar Health’s most followed narrative pegs fair value at $15.40, which sits below the last close at $18.49 and frames the recent price surge in a more cautious light.

Recent market-wide increases in morbidity within the individual ACA market highlight Oscar Health's vulnerability to dynamic risk pools, heightening uncertainty in claims costs and putting pressure on the company's ability to maintain or grow net margins and future earnings, even with planned repricing actions.

Curious what kind of revenue ramp, margin shift, and future earnings power are baked into that $15.40 fair value? The answer rests on a specific growth tempo, a step change in profitability, and a valuation multiple that has to line up with those forecasts.

Result: Fair Value of $15.40 (OVERVALUED)

However, strong regulatory scrutiny and higher cost risk pools, along with tighter data rules around Oscar’s technology, could still unsettle the fair value story investors are watching.

Another Angle On Value

The analyst narrative says Oscar Health looks about 20.1% overvalued versus a fair value of $15.40, but the current P/S ratio near 0.5x paints a different picture. That sits below the US Insurance industry at 1.1x, the peer average at 0.6x, and even a fair ratio of 0.7x. This suggests the market might still be pricing in some caution despite the recent share price run.

For you, the gap between the current 0.5x P/S and that 0.7x fair ratio is really about risk and timing. If the story around revenue forecasts, profitability and Lucie execution changes, does the market move closer to the higher ratio, or does the narrative pull expectations back toward the analyst fair value first? You may also want to consider which signal you will place more weight on if that happens.

Next Steps

With sentiment split between caution on risks and optimism on rewards, it may be useful to act promptly and test the numbers yourself using the 2 key rewards and 1 important warning sign

Looking for more investment ideas?

If Oscar Health has sharpened your curiosity, do not stop here. Broaden your watchlist now so you are not catching up after the next move.

• Spot potential value opportunities early by checking companies highlighted in the 50 high quality undervalued stocks.
• Prioritize resilience and sleep a little easier by focusing on stocks surfaced in the 69 resilient stocks with low risk scores.
• Hunt for income ideas that might support your portfolio cash flow using the 13 dividend fortresses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.